KeyMed Biosciences Inc (02162.HK)

Keymed Biosciences, Inc. is an investment holding company, which engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. The company is headquartered in Chengdu, Sichuan and currently employs 1,469 full-time employees. The company went IPO on 2021-07-08. The firm also focused on the research and development of pharmaceutical products. The firm's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm mainly conducts its businesses in the domestic market and overseas markets.